Navigation Links
Phase III study finds investigational agent empagliflozin significantly reduced blood glucose in adults with type 2 diabetes and impaired kidney function
Date:6/22/2013

RIDGEFIELD, Conn. and INDIANAPOLIS, June 22, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced results of a 52-week phase III clinical trial of the investigational agent empagliflozin*, which showed statistically significant reductions in HbA1c (average blood glucose) at week 24 with the addition of empagliflozin to existing oral antihyperglycemic therapy in adults with type 2 diabetes (T2D) and mild to moderate kidney impairment (eGFR>/=60 to <90 ml/min/1.73 m2 and eGFR>/=30 to <60 ml/min/1.73 m2).1

Empagliflozin is a member of the sodium glucose co-transporter-2 (SGLT2) inhibitor class of compounds, and is being investigated for the reduction of blood glucose levels in adults with T2D. The emerging SGLT2 inhibitor class removes excess glucose through the urine by blocking glucose re-absorption by the kidney.

Results from the study, presented at the American Diabetes Association 73rd Scientific Sessions®, also demonstrated a significant reduction in body weight and blood pressure with empagliflozin versus placebo in patients with mild to moderate kidney impairment.1 Adverse events (AEs) were reported in 79.6 percent, 75.4 percent and 72.7 percent of patients at 24 weeks with empagliflozin 10 mg, empagliflozin 25 mg and placebo, respectively.

"We are encouraged by the data from this phase III study," said Christophe Arbet-Engels, MD, PhD, vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "Many people with type 2 diabetes also are impacted by renal impairment. Through the Boehringer Ingelheim and Lilly Diabetes alliance, we are using our collective knowledge to find
'/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase III studies show linagliptin improved blood glucose control in Asian adults with type 2 diabetes
2. Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes
3. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
4. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
5. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
6. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
7. Safinamide Phase III Study Results Presented at 2013 MDS Meeting
8. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
9. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
10. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
11. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 Surgeons at The Children,s Hospital of ... report the first successful use of a SynCardia temporary ... with failing Fontan circulation to bridge him to a ... old, the patient received a Fontan circulation procedure to ... "The Fontan operation is the final planned palliative operation ...
(Date:9/16/2014)... Va. , Sept. 16, 2014 ... Medical Directors Institute has simultaneously released the NAMCP ... NAMCP Medical Diagnostics Dossier Template © , which ... template formats for either medical devices or diagnostics ... aspects of each of these technology types (instead ...
(Date:9/16/2014)... , Sept. 16, 2014 The Lupus ... LLY ) today released results from UNVEIL: ... sheds light on the lupus journey and the challenges ... for lupus caregivers. The UNVEIL study, which involved over ... devastating impact lupus has on all aspects of life ...
Breaking Medicine Technology:13-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 213-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 3NAMCP Medical Directors Institute releases NAMCP Medical Technologies and Diagnostics Dossier Templates to provide model approach for medical devices or diagnostics 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5
... The Netherlands, July 16 Neurofeedback - also,called EEG ... activity in order to,normalize Brain function and treat psychiatric ... 10 years, however the question,whether this treatment should be ... a study will be published in the scientific,journal ,EEG ...
... , , BOSTON and ... IIb multinational study(1) with edoxaban(2) - an investigational oral Factor ... atrial fibrillation (AF) receiving edoxaban once daily (QD) experienced fewer ... The analysis finds that bleeding associated with edoxaban is most ...
Cached Medicine Technology:New Research Shows: Neurofeedback is an 'Evidence-Based' Treatment for ADHD 2Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing 2Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing 3Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing 4Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing 5
(Date:9/16/2014)... Today, Top10BestSEOHosting.com compares many ... USA and announces that HostMonster, Arvixe and ... Windows web hosting companies in the market. ... high quality WordPress hosting (including VPS and ... HostMonster provides outstanding customer support and a ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Not all ... they take care to make sure all their patients ... For some, this may include the newly-introduced online therapy. ... program which gives patients the opportunity to seek treatment ... can provide medical and clinical care at a distance. ...
(Date:9/16/2014)... Aspen Advisors, a U.S.-based healthcare IT consulting firm, ... high morale and collaborative culture in the ... Work For 2014.” Consulting magazine publishes the popular ... participating across all major industries, representing more than 350 ... firms were ranked in six categories - firm culture, ...
(Date:9/16/2014)... may one day be able to predict when and ... sexual functioning, thanks in part to new findings that ... American Society for Radiation Oncology,s 56th Annual Meeting on ... more than 17,000 surveys completed by men diagnosed with ... and sexual symptoms changed following each type of treatment, ...
(Date:9/16/2014)... September 16, 2014 Who:, The Pulmonary ... Medical Campus and Children’s Hospital Colorado are ... the country’s leading pulmonary hypertension association that works to find ... disease of the lungs that affects the functioning of the ... mean survivability is only 2.8 years. , What:, Colorado ...
Breaking Medicine News(10 mins):Health News:Best Windows Web Hosting Suppliers Recommended By SEO Hosting Review Site Top10BestSEOHosting.com 2Health News:Millennium Treatment Group Now Offers Online Therapy 2Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 2Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 3Health News:Study identifies when and how much various prostate cancer treatments will impact urinary and sexual functioning 2Health News:Study identifies when and how much various prostate cancer treatments will impact urinary and sexual functioning 3Health News:Help Fight Pulmonary Hypertension at the Colorado PH in the Park 2014 2
... Insurance Convention Expected to Draw ... Protestors to San Francisco,Delgadillo to Discuss Legal Efforts to Crack Down ... and Unfair Business Acts and Practices" of Insurers, SAN ... of,protest against health insurance corporations, Los Angeles City Attorney,Rocky Delgadillo will ...
... the team that made the discovery, Professor Christopher Rowe ... and treatment presents medical practitioners with the best opportunity ... is at an experimental stage, this work places Australia ... Rowe says. , A 2004 Access Economics report calculated ...
... marks, get set go to lane 1? , ... connection between loud sounds and reaction time are reporting findings ... the upcoming Olympics. , Led by Dave Collins, professor ... hypothesized that the loud starter,s pistol at the Olympic Games ...
... Introduces ,The Insight, First ,Webisode, Featuring Guest, Hosts, Live Call-ins, ... ... Dealing With Change, BOCA RATON, Fla., ... Florida,s first weekly webisode -- a,transformational show called "The Insight" ...
... SAN CARLOS, Calif., June 18 Nuvelo, Inc.,(Nasdaq: ... the company,s chairman,and chief executive officer, will present at ... 2008, at 1:30 p.m. ET in New,York City., ... available online via,the Investor Relations portion of Nuvelo,s website ...
... ARAY ), a global leader in the field ... officer, Euan S.,Thomson, Ph.D., is scheduled to present at ... 10:15 a.m. EDT (7:15 a.m. PDT)., A live ... the,investor relations page of the Company,s Web site at, ...
Cached Medicine News:Health News:L.A. City Attorney Rocky Delgadillo, Patient Activists to Unveil New Television Ad Targeting Health Insurers 2Health News:L.A. City Attorney Rocky Delgadillo, Patient Activists to Unveil New Television Ad Targeting Health Insurers 3Health News:Advance towards early Alzheimer's diagnosis 2Health News:Sprinters closest to starter pistol have advantage over those farther away, says study 2Health News:A South Florida Premiere 2Health News:Accuray Incorporated's CEO to Speak at Jefferies Second Annual Healthcare Conference 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: